二甲双胍对晚期非小细胞肺癌合并糖尿病患者生存期影响的研究  

Study on the Effect of Metformin on the Survival Time of Patients with Advanced Non-small Cell Lung Cancer and Diabetes

作　　者：王丙乙 林翔[1] 黄超雄 WANG Bingyi;LIN Xiang;HUANG Chaoxiong(Department of Radiotherapy,Fujian Cancer Hospital,Fuzhou,Fujian Province,350014 China)

机构地区：[1]福建省肿瘤医院放疗科,福建福州350014

出　　处：《糖尿病新世界》2021年第22期65-67,71,共4页Diabetes New World Magazine

摘　　要：目的探讨二甲双胍对晚期非小细胞肺癌合并糖尿病患者生存期影响。方法选择2018年1月—2020年12月期间在该院接受治疗的100例晚期非小细胞肺癌合并糖尿病患者作为研究对象,行随机分组法将其分为两组,对照组和研究组患者各50例,两组患者均接受化疗,研究组另加用二甲双胍治疗,对比患者临床效果、不良反应情况及生存质量。结果研究组临床效果(76.00%)高于对照组(42.00%),差异有统计学意义(χ^(2)=11.947,P<0.001);研究组肝肾毒性、消化道反应、Ⅲ/Ⅳ度骨髓抑制低于对照组,差异有统计学意义(χ^(2)=4.000、10.714、8.274,P=0.046、0.001、0.004);研究组生存质量各指标评分高于对照组,差异有统计学意义(t=11.920、12.779、13.467、13.771、9.543、9.102,P<0.001)。结论晚期非小细胞肺癌合并糖尿病患者化疗期间加用二甲双胍治疗,临床效果优于单纯化疗,且不良反应率低,对患者生存期影响较小,可有效提高生存质量。Objective To investigate the impact of metformin on the survival of patients with advanced non-small cell lung cancer and diabetes. Methods 100 patients with advanced non-small cell lung cancer combined with diabetes who were treated in the hospital from January 2018 to December 2020 were selected as the subjects of this study. They were divided into two groups by randomization method, the control group and the study group. There were 50 patients in each group. Both groups received chemotherapy, and the study group was additionally treated with metformin. The clinical effects, adverse reactions and quality of life of the patients were compared. Results The clinical effect of the study group(76.00%) was higher than that of the control group(42.00%), and the difference was statistically significant(χ^(2)=11.947, P<0.001);the study group had liver and kidney toxicity, gastrointestinal reactions, and grade Ⅲ/Ⅳ bone marrow inhibition was lower than that of the control group, and the difference was statistically significant(χ^(2)=4.000, 10.714, 8.274, P=0.046, 0.001, 0.004);the quality of life index scores of the study group were higher than those of the control group, and the difference was statistically significant(t=11.920, 12.779, 13.467, 13.771, 9.543, 9.102, P<0.001). Conclusion Patients with advanced non-small cell lung cancer combined with diabetes mellitus are treated with metformin during chemotherapy, the clinical effect is better than chemotherapy alone, and the adverse reaction rate is low. It has less impact on the survival of patients and can effectively improve the quality of life.

关 键 词：二甲双胍 晚期 非小细胞肺癌 糖尿病 生存期 

分 类 号：R59[医药卫生—内科学]